Acrongenomics Acquires Equity Stake in Molecular Vision

Geneva (ots/PRNewswire) - Acrongenomics, Inc. (OTC: AGNM) is
pleased to announce that they have acquired a 10.9% interest in
Molecular Vision Limited, on a fully diluted basis. The cash
consideration will be used by Molecular Vision for working capital
and to further develop its technology.

Molecular Vision is developing low cost easy-to-use credit-card
sized devices for medical testing that will greatly extend the
in-house tools available to the general practitioner. The devices are
being developed to allow near patient quantitative diagnosis,
currently focusing on key areas of high disease burden, namely kidney
function and cardiovascular disease. The technology also has
additional applications outside the diagnostics market (e.g. forensic
science, homeland security and environmental monitoring).

About Acrongenomics Inc.

Acrongenomics Inc. is a publicly traded company that focuses on
investing in and commercializing novel technology platforms
concerning the Life Sciences sector. Acrongenomics brings novel and
realistic concepts to market by transforming scientific innovations
into tangible, consumer-orientated applications. The company has its
headquarters in Geneva, Switzerland.

About Molecular Vision Limited

Molecular Vision Limited is a spin-out company of Imperial
college, London UK. The company was founded by three Imperial College
London researchers - Prof. Donal Bradley, Prof. Andrew De Mello and
Dr. John De Mello - in 2002 in order to meet a clearly defined demand
in the medical diagnostics, biosensors and analytical
instrumentations markets and the need for miniaturized chemical and
biological detectors offering high sensitivity and functionality at
low cost. The company has directly addressed this market demand by
inventing a novel method for optical detection based on recent
advances in organic electronics and light emitting diodes combined
with microfluidics technology. The company has mainly focused on
applying its technology to the medical diagnostics markets.

Important Information About Forward-Looking Statements

All statements in this news release that are other than statements
of historical facts are forward-looking statements which contain our
current expectations about our future results. Forward-looking
statements involve numerous risks and uncertainties. We have
attempted to identify any forward-looking statements by using words
such as "anticipates", "believes", "could", "expects", "intends",
"may", "should" and other similar expressions. Although we believe
that the expectations reflected in all of our forward looking
statements are reasonable, we can give no assurance that such
expectations will prove to be correct. A number of factors may affect
our future results and may cause those results to differ materially
from those indicated in any forward-looking statements made by us or
on our behalf. Such factors include our limited operating history;
our need for significant capital to finance internal growth as well
as strategic acquisitions; our ability to attract and retain key
employees and strategic partners; our ability to achieve and maintain
profitability; fluctuations in the trading price and volume of our
stock; competition from other providers of similar products and
services; and other unanticipated future events and conditions. For
further information concerning risks and uncertainties that may
affect our future results, please review the disclosures contained in
our latest filings with the SEC, including our most recent annual
report on Form 10-KSB, and subsequent quarterly reports on Form
10-QSB. Other than as required by federal securities laws, we
undertake no obligation to publicly update or revise any of our
forward-looking statements, whether as a result of changed
circumstances, new information, future events, or for any other
reason occurring after the date of this news release.

For more information contact:
Acrongenomics Inc.
Platon M Tzouvalis
President
Tel: +41-22-716-5300
Fax: +41-22-716-5319
http://www.acrongen.com

ots Originaltext: Acrongenomics Inc.
Im Internet recherchierbar: http://www.presseportal.de

$story.getcontactHeadline()
For more information contact: Acrongenomics Inc., Platon M Tzouvalis,
President, Tel: +41-22-716-5300, Fax: +41-22-716-5319,
http://www.acrongen.com